Lifecore Acquired by Webster Equity Partners

Strategic Rationale

• Accelerate Commercialization: Leverage Webster’s capital and healthcare expertise to advance Lifecore’s late-stage pipeline and support new commercial launches.

• Improve Capacity Utilization: Increase production volumes across existing sterile injectable facilities to improve operating leverage and EBITDA margins.

• Strengthen Financial Position: Address existing debt obligations and preferred-stock redemption requirements through acquisition financing.

• Diversify Customer Base: Expand beyond Alcon by securing new pharmaceutical customers and commercial manufacturing contracts.

• Enhance Shareholder Value: Provide immediate cash consideration at a premium, alongside potential contingent payments tied to future performance.

Management Commentary

• Paul Josephs, CEO: Highlighted 13 late-stage programs with commercialization potential by 2028, supporting future revenue growth and customer diversification.

• Paul Josephs, CEO: Emphasized the extension of Alcon’s manufacturing agreement through 2034, strengthening long-term revenue visibility.

• Paul Josephs, CEO: Outlined targets of 12% revenue CAGR and adjusted EBITDA margins exceeding 25% by 2029, supported by commercial launches and operational improvements.

• Matthew Beer, Webster Partner: Highlighted the opportunity to combine Webster’s healthcare expertise with Lifecore’s CDMO capabilities to improve operational efficiency and achieve sustainable profitability.

Lifecore Biomedical Overview

Business Model

• Lifecore Biomedical is a specialized CDMO focused on complex sterile injectables and pharmaceutical-grade hyaluronic acid (HA).

• Provides end-to-end development and manufacturing services, from formulation and analytical testing to commercial-scale production.

• Generates revenue through development fees, long-term manufacturing contracts, and HA product sales, supported by recurring commercial production.

Product Overview

• Hyaluronic Acid (HA): Manufactures pharmaceutical-grade HA for ophthalmic, orthopedic, and aesthetic applications using proprietary fermentation technology.

• Sterile Injectable Products: Produces complex HA-based and non-HA injectable pharmaceuticals and medical devices.

• Aseptic Fill-Finish: Provides sterile filling and packaging for prefilled syringes, vials, and cartridges.

• Development Services: Offers formulation development, analytical testing, process validation, technology transfer, and clinical trial manufacturing.

Geographic Footprint

Financial Overview

Major Customers

Evolution of Lifecore Biomedical

Synergy with Webster Equity Partner Portfolio Companies

Pharma CDMO Industry Outlook

• Growth in Pharmaceutical Outsourcing: Increasing drug complexity and R&D spending continue to drive outsourcing demand, with the global CDMO market projected to grow at approximately 17% annually through 2032, depending on market definition.

• Rising Demand for Sterile Injectables: Growth in biologics, GLP-1 therapies, and complex formulations is supporting demand for aseptic fill-finish services, with the market projected to reach $21B by 2030.

• Private Equity and M&A Consolidation: The fragmented CDMO market continues to attract investors seeking specialized manufacturing capabilities and opportunities to build broader pharmaceutical services platforms.

• Shift Toward Domestic Manufacturing: Pharmaceutical companies are increasingly prioritizing U.S. and European manufacturing facilities to reduce geopolitical and supply chain risks.

• Capacity Utilization and Margin Expansion: CDMOs can improve profitability by increasing production volumes across existing facilities, while integrated platforms offer potential cross-selling opportunities and operational efficiencies.

Radiopharmaceutical contract development and manufacturing organizations (CDMOs) are becoming critical infrastructure for nuclear medicine. The global market is projected to grow from $3.2 billion in 2025 to $7.5 billion by 2034, supported by increasing outsourcing and more than 260 active therapeutic trials. Growth remains constrained by isotope availability, qualified GMP capacity and specialist talent.

Market Scope

· Precursor & Isotope Supply: Enrichment and production of medical radioisotopes through reactors, accelerators and generators.

· Equipment & Manufacturing: Shielded infrastructure, radiolabeling, formulation, sterile fill-finish and quality control.

· Development & Clinical Services: Therapeutic development, trial execution, imaging, dosimetry and regulatory support.

· Distribution & Diagnostics: Patient-specific dose preparation, timely delivery and PET/SPECT imaging for patient selection and monitoring.

Market Trends

· Capacity Expansion: CDMOs are adding GMP facilities and broader manufacturing networks.

· Isotope Security: Long-term supply agreements and redundant sourcing are becoming competitive advantages.

· Alpha-Therapy Investment: Ac-225 and Pb-212 are attracting investment alongside established Lu-177 therapies.

· Vertical Integration: Companies are combining isotope production, manufacturing and distribution to reduce supply risk.

· Longer-Term Contracts: Technology-transfer fees, capacity reservations and multi-year agreements improve revenue visibility.

· Decay-Driven Geography: Short-lived isotopes favor production close to treatment centers.

Radiopharma Industry Structure

Investor Considerations

• Precursor & Enrichment: Secure feedstock and specialized enrichment capabilities create barriers to entry; concentrated supply adds geopolitical risk.

• Isotope Production: High capital requirements make utilization and long-term contracts critical; emerging isotopes carry production and clinical risks.

• Equipment & Infrastructure: Recurring service revenue supports earnings, while long production and installation cycles pressure cash flow.

• CDMO & Manufacturing: Contracted utilization, take-or-pay agreements and regulatory compliance matter more than installed capacity alone.

• Developers & Sponsors: Clinical maturity and approval prospects drive valuation; proprietary platforms can offer greater strategic value.

• Specialist CRO & Clinical: Growing trial activity supports demand; software adds recurring revenue, while talent shortages constrain capacity.

• Radiopharmacy & Distribution: Dense local networks create competitive advantages, but regional expansion requires substantial investment.

• Diagnostics & Imaging: Reimbursement, commercial demand and reliable local distribution shape adoption and investment value.

Integrated Platforms & Investor Positioning

Private Investor Insights

M&A & Platform Consolidation

See the Full Report Below

Radiopharma Cdmo Market Insight

2.05MB ∙ PDF file

Download

Download

The discussion below summarizes the principal themes. The full deck is attached for transaction detail, market maps, company examples and segment-level analysis.

Cdmo Market Insights Jun 2026 08

3.21MB ∙ PDF file

Download

Download

Market Growth Remains Structurally Attractive

The global CDMO market is estimated at approximately $195–220 billion in 2025 and is expected to grow at a 7–8% CAGR, reaching approximately $320–420 billion by 2032–2034.

Small-molecule API and oral solid dose remain the largest revenue pools, while biologics, sterile injectables, ADCs and other advanced modalities represent faster-growing areas. Continued pharmaceutical outsourcing remains a core driver, with sponsors increasingly using external manufacturing partners to avoid large capital commitments and gain access to specialized technical capabilities.

Consolidation Continues Across the CDMO Landscape

Strategic buyers and private equity sponsors remain active across the sector. Recent transactions have targeted sterile fill-finish, biologics, peptides and oligonucleotides, complex oral formulations and advanced manufacturing capabilities.

The broader M&A trend is toward larger, more integrated platforms that can support customers from development through commercial manufacturing. At the same time, specialist assets remain attractive where capabilities are difficult to replicate, capacity is qualified and customer demand is visible.

Despite consolidation, the market remains fragmented, with the largest CDMOs representing a relatively small share of the overall market. This continues to support platform-building and add-on acquisition strategies.

Policy and Supply-Chain Changes Are Reshaping Sourcing

Supply-chain resilience is becoming a more important consideration in pharmaceutical manufacturing.

The report highlights the BIOSECURE Act, China+1 sourcing strategies and U.S. pharmaceutical onshoring initiatives as factors influencing where sponsors place manufacturing programs.

FDA initiatives intended to streamline domestic manufacturing expansion may also support investment in U.S. API and finished-dose capacity. Existing domestic CDMOs with compliant infrastructure, available capacity and strong regulatory records may be particularly well positioned as sponsors diversify supply chains.

Biosimilars Could Support Additional Biologics Outsourcing

Changes to the U.S. biosimilar approval framework could create another demand tailwind for biologics CDMOs.

Reduced clinical requirements may lower development barriers for selected biosimilar programs, potentially expanding the number of companies pursuing commercialization. Smaller and mid-sized developers often lack internal biologics manufacturing infrastructure, creating potential outsourcing demand across development, analytical testing, scale-up and commercial production.

The strongest positioning remains with CDMOs that combine qualified biologics capacity with commercial manufacturing experience and regulatory credibility.

The CDMO Model Remains Capital Efficient for Drug Developers

Building specialized pharmaceutical manufacturing infrastructure can require hundreds of millions of dollars and several years of qualification and validation.

CDMOs allow drug developers to avoid these fixed investments while accessing specialized facilities, experienced technical teams, quality systems and regulatory infrastructure. Integrated providers can also support formulation, analytical development, clinical manufacturing and commercial supply within one organization.

For CDMOs, the business model becomes more attractive as programs move from project-based development work into validated, recurring commercial manufacturing. Commercial supply agreements, minimum-volume commitments and capacity reservations can improve revenue visibility, while regulatory filings and technology-transfer requirements create meaningful customer switching friction.

Summary

The CDMO market continues to benefit from outsourcing, pharmaceutical pipeline complexity and supply-chain diversification. However, growth is increasingly concentrated in specialized capabilities rather than across manufacturing capacity broadly.

Across the sector, the strongest positioning is generally found where technical differentiation, qualified capacity, commercial manufacturing experience and regulatory execution come together.

The attached Pharma CDMO Market Insights – August 2026 deck provides the full transaction analysis, market maps, policy discussion, business-model framework and segment-level detail.

Cdmo Market Insights Jun 2026 08

3.21MB ∙ PDF file

Download

Download